<!DOCTYPE html>
<html lang="pt-BR">
<head>
    <meta charset="utf-8"/>
    <meta content="width=device-width, initial-scale=1.0" name="viewport"/>
    <title>Relat√≥rio de Intelig√™ncia - Judicializa√ß√£o de Medicamentos</title>
    <link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css" rel="stylesheet"/>
    <style>
        :root {
            --primary-color: #003366;
            --secondary-color: #004080;
            --accent-color: #0066cc;
            --light-color: #e6eef7;
            --success-color: #28a745;
            --warning-color: #ffc107;
            --danger-color: #dc3545;
            --info-color: #17a2b8;
            --gray-color: #6c757d;
            --light-gray-color: #f8f9fa;
            --dark-gray-color: #343a40;
        }
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
        }
        
        body {
            background-color: #f5f7fa;
            color: #333;
            line-height: 1.6;
        }
        
        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 15px;
        }
        
        header {
            background-color: var(--primary-color);
            color: white;
            padding: 20px 0;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
        }
        
        .header-content {
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .logo {
            font-size: 24px;
            font-weight: 700;
            display: flex;
            align-items: center;
        }
        
        .logo img {
            height: 40px;
            margin-right: 10px;
        }
        
        .header-info {
            text-align: right;
        }
        
        .header-title {
            font-size: 20px;
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .header-date {
            font-size: 14px;
            opacity: 0.9;
        }
        
        main {
            padding: 30px 0;
        }
        
        section {
            background: white;
            border-radius: 8px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.05);
            padding: 25px;
            margin-bottom: 30px;
        }
        
        .section-title {
            color: var(--primary-color);
            font-size: 20px;
            font-weight: 600;
            margin-bottom: 20px;
            padding-bottom: 10px;
            border-bottom: 2px solid var(--light-color);
            display: flex;
            align-items: center;
        }
        
        .section-title i {
            margin-right: 10px;
            color: var(--secondary-color);
        }
        
        .stats-container {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(240px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        
        .stat-card {
            background: white;
            border-radius: 8px;
            padding: 20px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            border-left: 4px solid var(--primary-color);
            transition: transform 0.3s ease;
        }
        
        .stat-card:hover {
            transform: translateY(-5px);
        }
        
        .stat-card.info {
            border-left-color: var(--info-color);
        }
        
        .stat-card.success {
            border-left-color: var(--success-color);
        }
        
        .stat-card.warning {
            border-left-color: var(--warning-color);
        }
        
        .stat-card.danger {
            border-left-color: var(--danger-color);
        }
        
        .stat-title {
            color: var(--gray-color);
            font-size: 14px;
            margin-bottom: 10px;
        }
        
        .stat-value {
            font-size: 24px;
            font-weight: 700;
            color: var(--dark-gray-color);
            margin-bottom: 5px;
        }
        
        .stat-description {
            font-size: 12px;
            color: var(--gray-color);
        }
        
        .chart-container {
            margin: 20px 0;
            position: relative;
        }
        
        .chart-title {
            font-size: 16px;
            font-weight: 600;
            color: var(--primary-color);
            margin-bottom: 10px;
            text-align: center;
        }
        
        .grid-2 {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 20px;
        }
        
        .grid-3 {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 20px;
        }
        
        .process-highlight {
            background: var(--light-color);
            border-radius: 8px;
            padding: 20px;
            margin-bottom: 20px;
        }
        
        .process-title {
            color: var(--primary-color);
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 15px;
        }
        
        .process-detail {
            margin-bottom: 10px;
        }
        
        .process-label {
            font-weight: 600;
            color: var(--dark-gray-color);
        }
        
        .process-value {
            color: var(--gray-color);
        }
        
        .status-chip {
            display: inline-block;
            padding: 5px 10px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            margin-right: 5px;
            margin-bottom: 5px;
        }
        
        .status-chip.deferido {
            background-color: rgba(40, 167, 69, 0.2);
            color: var(--success-color);
        }
        
        .status-chip.indeferido {
            background-color: rgba(220, 53, 69, 0.2);
            color: var(--danger-color);
        }
        
        .status-chip.pendente {
            background-color: rgba(255, 193, 7, 0.2);
            color: var(--warning-color);
        }
        
        .recommendations {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
        }
        
        .recommendation-card {
            background: white;
            border-radius: 8px;
            padding: 20px;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            border-top: 4px solid var(--accent-color);
        }
        
        .recommendation-title {
            font-size: 16px;
            font-weight: 600;
            color: var(--primary-color);
            margin-bottom: 10px;
        }
        
        .recommendation-list {
            list-style-type: none;
        }
        
        .recommendation-item {
            margin-bottom: 8px;
            padding-left: 20px;
            position: relative;
        }
        
        .recommendation-item:before {
            content: "‚Üí";
            position: absolute;
            left: 0;
            color: var(--accent-color);
        }
        
        .table-container {
            overflow-x: auto;
            margin-bottom: 20px;
        }
        
        table {
            width: 100%;
            border-collapse: collapse;
        }
        
        th, td {
            padding: 12px 15px;
            text-align: left;
            border-bottom: 1px solid #e0e0e0;
        }
        
        th {
            background-color: var(--light-color);
            color: var(--primary-color);
            font-weight: 600;
        }
        
        tr:hover {
            background-color: #f9f9f9;
        }
        
        .metadata {
            background-color: var(--light-gray-color);
            padding: 15px;
            border-radius: 8px;
            font-size: 12px;
            color: var(--gray-color);
            margin-top: 40px;
        }
        
        .metadata-title {
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .metadata-item {
            margin-bottom: 3px;
        }
        
        footer {
            background-color: var(--primary-color);
            color: white;
            padding: 20px 0;
            text-align: center;
            font-size: 14px;
        }
        
        .footer-links {
            margin-top: 10px;
        }
        
        .footer-links a {
            color: white;
            margin: 0 10px;
            text-decoration: none;
        }
        
        .footer-links a:hover {
            text-decoration: underline;
        }
        
        .spacer {
            height: 40px;
            width: 100%;
        }
        
        .table-with-bars td {
            position: relative;
        }
        
        .table-bar {
            position: absolute;
            height: 70%;
            background-color: rgba(0, 51, 102, 0.1);
            left: 0;
            top: 15%;
            z-index: 0;
        }
        
        .table-text {
            position: relative;
            z-index: 1;
        }
        
        .trend-indicator {
            display: inline-flex;
            align-items: center;
            margin-left: 10px;
            font-size: 14px;
        }
        
        .trend-up {
            color: var(--success-color);
        }
        
        .trend-down {
            color: var(--danger-color);
        }
        
        @media (max-width: 768px) {
            .grid-2, .grid-3 {
                grid-template-columns: 1fr;
            }
            
            .header-content {
                flex-direction: column;
                text-align: center;
            }
            
            .header-info {
                text-align: center;
                margin-top: 10px;
            }
            
            .stats-container {
                grid-template-columns: 1fr;
            }
        }
        
        /* Anima√ß√µes */
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        
        section {
            animation: fadeIn 0.5s ease-in-out;
        }
        
        .print-button {
            position: fixed;
            bottom: 20px;
            right: 20px;
            background-color: var(--primary-color);
            color: white;
            border: none;
            border-radius: 50%;
            width: 50px;
            height: 50px;
            display: flex;
            justify-content: center;
            align-items: center;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.2);
            cursor: pointer;
            transition: all 0.3s ease;
            z-index: 100;
        }
        
        .print-button:hover {
            background-color: var(--secondary-color);
            transform: scale(1.1);
        }
        
        @media print {
            body {
                background-color: white;
            }
            
            section {
                box-shadow: none;
                margin-bottom: 15px;
                break-inside: avoid;
            }
            
            .print-button {
                display: none;
            }
        }
    </style>
</head>
<body>
<header>
    <div class="container">
        <div class="header-content">
            <div class="logo">
                <svg width="40" height="40" viewBox="0 0 54 54" fill="none" xmlns="http://www.w3.org/2000/svg">
                    <rect width="54" height="54" rx="10" fill="white"/>
                    <path d="M12 14H42M12 27H42M12 40H42" stroke="white" stroke-width="4" stroke-linecap="round"/>
                    <path d="M27 9V45" stroke="white" stroke-width="4" stroke-linecap="round"/>
                    <path d="M17 9L37 45" stroke="white" stroke-width="4" stroke-linecap="round"/>
                    <path d="M37 9L17 45" stroke="white" stroke-width="4" stroke-linecap="round"/>
                </svg>
                <span>MEEDI</span>
            </div>
            <div class="header-info">
                <div class="header-title">Relat√≥rio de Intelig√™ncia - Judicializa√ß√£o de Medicamentos</div>
                <div class="header-date">Emitido em: 24/04/2025</div>
            </div>
        </div>
    </div>
</header>

<main class="container">
    <!-- Se√ß√£o de Vis√£o Geral -->
    <section>
        <h2 class="section-title"><i class="fas fa-chart-pie"></i> Vis√£o Geral</h2>
        
        <!-- Cards de Estat√≠sticas Principais -->
        <div class="stats-container">
            <div class="stat-card info">
                <div class="stat-title">Total de Processos Analisados</div>
                <div class="stat-value">6</div>
                <div class="stat-description">TJGO, TJSE (2024-2025)</div>
            </div>
            <div class="stat-card success">
                <div class="stat-title">Taxa de Tutelas Deferidas</div>
                <div class="stat-value">100%</div>
                <div class="stat-description">Todos os pedidos concedidos</div>
            </div>
            <div class="stat-card warning">
                <div class="stat-title">Maior Valor Pleiteado</div>
                <div class="stat-value">R$ 1,5 mi</div>
                <div class="stat-description">Tratamento de 2 anos (Keytruda)</div>
            </div>
            <div class="stat-card danger">
                <div class="stat-title">Prazo M√©dio de Infus√£o</div>
                <div class="stat-value">21 dias</div>
                <div class="stat-description">Para imunobiol√≥gicos</div>
            </div>
        </div>
    </section>

    <!-- Processo em Destaque - Pembrolizumabe -->
    <section>
        <h2 class="section-title"><i class="fas fa-file-medical"></i> Pembrolizumabe (Keytruda)</h2>
        
        <div class="process-highlight">
            <div class="process-title">üìÇ Processos Analisados (4 casos)</div>
            <div class="process-detail"><span class="process-label">Processos:</span> <span class="process-value">5688664-48.2024.8.09.0051 (TJGO, Goi√¢nia ‚Äì 6¬™ UPJ); 5122485-92.2024.8.09.0051 (TJGO); 202411801605 (TJSE, Aracaju); 5980068-02.2024.8.09.0051 (TJGO)</span></div>
            <div class="process-detail"><span class="process-label">Classe Processual:</span> <span class="process-value">A√ß√£o de Obriga√ß√£o de Fazer c/c Indeniza√ß√£o por Danos Morais (2); Procedimento Comum C√≠vel (2)</span></div>
            <div class="process-detail"><span class="process-label">Tutelas:</span> <span class="status-chip deferido">100% deferidas</span></div>
        </div>
        
        <div class="chart-title">Dados M√©dicos</div>
        <div class="process-highlight">
            <div class="process-detail"><span class="process-label">Defini√ß√£o:</span> <span class="process-value">Anticorpo anti-PD-1 usado em diversos tipos de c√¢ncer avan√ßado</span></div>
            <div class="process-detail"><span class="process-label">Indica√ß√µes Pleiteadas:</span></div>
            <ul style="list-style-type: disc; margin-left: 25px; margin-bottom: 15px;">
                <li><strong>Carcinoma de mama triplo-negativo metast√°tico:</strong> com quimioterapia combinada (Paclitaxel 80 mg/m¬≤ + Carboplatina AUC2 por 12 ciclos)</li>
                <li><strong>C√¢ncer colorretal metast√°tico MSI-H:</strong> imunoterapia combinada com Durvalumabe (1500 mg a cada 28 dias)</li>
                <li><strong>Linfoma de Hodgkin (CID C81):</strong> em combina√ß√£o com Nivolumabe (Opdivo)</li>
                <li><strong>Carcinoma de cabe√ßa e pesco√ßo (orofaringe):</strong> monoterapia por 2 anos (cerca de 35 ciclos)</li>
            </ul>
            <div class="process-detail"><span class="process-label">Dosagens:</span> <span class="process-value">200 mg EV a cada 21 dias (padr√£o em todos os casos)</span></div>
            <div class="process-detail"><span class="process-label">Alternativas:</span> <span class="process-value">N√£o foram identificadas alternativas terap√™uticas vi√°veis nos casos analisados</span></div>
        </div>
        
        <div class="grid-2">
            <div>
                <div class="chart-title">Dados Jur√≠dicos</div>
                <div class="process-highlight">
                    <div class="process-detail"><span class="process-label">Fundamentos dos Pedidos:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px; margin-bottom: 15px;">
                        <li>Inefic√°cia das alternativas convencionais</li>
                        <li>Gravidade do quadro oncol√≥gico</li>
                        <li>Prescri√ß√£o m√©dica espec√≠fica</li>
                        <li>An√°lises do NATJUS (favor√°veis)</li>
                    </ul>
                    <div class="process-detail"><span class="process-label">Argumentos da Defesa:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px;">
                        <li>Falta de previs√£o no Rol da ANS</li>
                        <li>Suposta natureza "off-label" de indica√ß√µes</li>
                    </ul>
                </div>
            </div>
            
            <div>
                <div class="chart-title">Dados Financeiros</div>
                <div class="process-highlight">
                    <div class="process-detail"><span class="process-label">Valores Pleiteados:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px; margin-bottom: 15px;">
                        <li>R$ 40.783,92 (quimioterapia + imunoterapia)</li>
                        <li>R$ 170.000,00 (tratamento de longa dura√ß√£o)</li>
                        <li>R$ 10.000,00 (tratamento imunoter√°pico)</li>
                        <li>R$ 1.539.965,70 (tratamento de 2 anos de Keytruda)</li>
                    </ul>
                    <div class="process-detail"><span class="process-label">Fontes Pagadoras:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px;">
                        <li>Ipasgo (plano de sa√∫de dos servidores de GO)</li>
                        <li>Estado de GO (via SUS estadual)</li>
                        <li>Estado de SE/munic√≠pio de Aracaju</li>
                    </ul>
                </div>
            </div>
        </div>
    </section>

    <!-- Processo de Imunoglobulina Humana -->
    <section>
        <h2 class="section-title"><i class="fas fa-file-medical"></i> Imunoglobulina Humana (Intravenosa)</h2>
        
        <div class="process-highlight">
            <div class="process-title">üìÇ Processos Analisados (2 casos)</div>
            <div class="process-detail"><span class="process-label">Processos:</span> <span class="process-value">5877812-78.2024.8.09.0051 (TJGO, Goi√¢nia - 1¬™ Vara da Fazenda P√∫blica); 5275973-25.2024.8.09.0162 (TJGO, Valpara√≠so de Goi√°s)</span></div>
            <div class="process-detail"><span class="process-label">Classe Processual:</span> <span class="process-value">Mandado de Seguran√ßa C√≠vel (1); Obriga√ß√£o de Fazer c/c Indeniza√ß√£o (1)</span></div>
            <div class="process-detail"><span class="process-label">Tutelas:</span> <span class="status-chip deferido">100% deferidas</span></div>
        </div>
        
        <div class="chart-title">Dados M√©dicos</div>
        <div class="process-highlight">
            <div class="process-detail"><span class="process-label">Defini√ß√£o:</span> <span class="process-value">Terapia de reposi√ß√£o imunol√≥gica para suporte em diversas condi√ß√µes</span></div>
            <div class="process-detail"><span class="process-label">Indica√ß√µes Pleiteadas:</span></div>
            <ul style="list-style-type: disc; margin-left: 25px; margin-bottom: 15px;">
                <li><strong>Rejei√ß√£o de transplante de √≥rg√£o (CID T86.1):</strong> terapia de suporte imunol√≥gico para fal√™ncia do enxerto</li>
                <li><strong>Outro caso n√£o detalhado:</strong> poss√≠vel imunodefici√™ncia adquirida ou doen√ßa autoimune</li>
            </ul>
            <div class="process-detail"><span class="process-label">Dosagens:</span> <span class="process-value">18 ampolas mensais por 6 meses (caso 1); dosagem indefinida at√© recupera√ß√£o cl√≠nica (caso 2)</span></div>
        </div>
        
        <div class="grid-2">
            <div>
                <div class="chart-title">Dados Jur√≠dicos</div>
                <div class="process-highlight">
                    <div class="process-detail"><span class="process-label">Fundamentos dos Pedidos:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px; margin-bottom: 15px;">
                        <li>Direito l√≠quido e certo ao tratamento</li>
                        <li>Dignidade humana e direito fundamental √† sa√∫de</li>
                        <li>Negativa de cobertura (caso Unimed)</li>
                    </ul>
                    <div class="process-detail"><span class="process-label">Argumentos da Defesa:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px;">
                        <li>Aus√™ncia de previs√£o contratual/legislativa</li>
                        <li>N√£o inscri√ß√£o no rol da ANS</li>
                    </ul>
                </div>
            </div>
            
            <div>
                <div class="chart-title">Dados Financeiros</div>
                <div class="process-highlight">
                    <div class="process-detail"><span class="process-label">Valores Pleiteados:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px; margin-bottom: 15px;">
                        <li>R$ 244.884,60 (tratamento de 6 meses com 18 ampolas mensais)</li>
                        <li>R$ 10.000,00 (estimativa inicial ou valor simb√≥lico)</li>
                    </ul>
                    <div class="process-detail"><span class="process-label">Fontes Pagadoras:</span></div>
                    <ul style="list-style-type: disc; margin-left: 25px;">
                        <li>Estado de Goi√°s (via SUS estadual)</li>
                        <li>Central Nacional Unimed (plano de sa√∫de)</li>
                    </ul>
                </div>
            </div>
        </div>
    </section>

    <!-- An√°lise Comparativa -->
    <section>
        <h2 class="section-title"><i class="fas fa-balance-scale"></i> An√°lise Comparativa</h2>
        
        <div class="chart-title">Distribui√ß√£o por Tipos de Medicamentos</div>
        <div class="chart-container">
            <div style="width: 100%;">
                <div style="margin-bottom: 15px;">
                    <div style="display: flex; align-items: center;">
                        <div style="width: 20px; height: 20px; background-color: #003366; margin-right: 10px; border-radius: 3px;"></div>
                        <div style="width: 170px; font-weight: bold;">Pembrolizumabe (Keytruda)</div>
                        <div style="flex-grow: 1; background-color: #f0f0f0; height: 25px; border-radius: 4px; overflow: hidden;">
                            <div style="background-color: #003366; width: 66.6%; height: 100%;"></div>
                        </div>
                        <div style="width: 50px; text-align: right; margin-left: 10px; font-weight: bold;">66,6%</div>
                    </div>
                </div>
                <div style="margin-bottom: 15px;">
                    <div style="display: flex; align-items: center;">
                        <div style="width: 20px; height: 20px; background-color: #0066cc; margin-right: 10px; border-radius: 3px;"></div>
                        <div style="width: 170px; font-weight: bold;">Imunoglobulina Humana</div>
                        <div style="flex-grow: 1; background-color: #f0f0f0; height: 25px; border-radius: 4px; overflow: hidden;">
                            <div style="background-color: #0066cc; width: 33.3%; height: 100%;"></div>
                        </div>
                        <div style="width: 50px; text-align: right; margin-left: 10px; font-weight: bold;">33,3%</div>
                    </div>
                </div>
            </div>
        </div>
        
        <div class="spacer"></div>
        
        <div class="chart-title">Distribui√ß√£o por Tipo de Doen√ßa</div>
        <div class="chart-container">
            <div style="width: 100%;">
                <div style="margin-bottom: 15px;">
                    <div style="display: flex; align-items: center;">
                        <div style="width: 20px; height: 20px; background-color: #003366; margin-right: 10px; border-radius: 3px;"></div>
                        <div style="width: 170px; font-weight: bold;">C√¢ncer (diversos tipos)</div>
                        <div style="flex-grow: 1; background-color: #f0f0f0; height: 25px; border-radius: 4px; overflow: hidden;">
                            <div style="background-color: #003366; width: 66.6%; height: 100%;"></div>
                        </div>
                        <div style="width: 50px; text-align: right; margin-left: 10px; font-weight: bold;">66,6%</div>
                    </div>
                </div>
                <div style="margin-bottom: 15px;">
                    <div style="display: flex; align-items: center;">
                        <div style="width: 20px; height: 20px; background-color: #0066cc; margin-right: 10px; border-radius: 3px;"></div>
                        <div style="width: 170px; font-weight: bold;">Rejei√ß√£o de Transplante</div>
                        <div style="flex-grow: 1; background-color: #f0f0f0; height: 25px; border-radius: 4px; overflow: hidden;">
                            <div style="background-color: #0066cc; width: 16.7%; height: 100%;"></div>
                        </div>
                        <div style="width: 50px; text-align: right; margin-left: 10px; font-weight: bold;">16,7%</div>
                    </div>
                </div>
                <div style="margin-bottom: 15px;">
                    <div style="display: flex; align-items: center;">
                        <div style="width: 20px; height: 20px; background-color: #3399ff; margin-right: 10px; border-radius: 3px;"></div>
                        <div style="width: 170px; font-weight: bold;">Outras (n√£o especificadas)</div>
                        <div style="flex-grow: 1; background-color: #f0f0f0; height: 25px; border-radius: 4px; overflow: hidden;">
                            <div style="background-color: #3399ff; width: 16.7%; height: 100%;"></div>
                        </div>
                        <div style="width: 50px; text-align: right; margin-left: 10px; font-weight: bold;">16,7%</div>
                    </div>
                </div>
            </div>
        </div>
        
        <div class="spacer"></div>
        
        <!-- Tabela de Comparativo de Custos -->
        <div class="section-title"><i class="fas fa-dollar-sign"></i> Comparativo de Custos</div>
        <div class="table-container">
            <table class="table-with-bars">
                <thead>
                    <tr>
                        <th>Processo</th>
                        <th>Medicamento</th>
                        <th>Valor Pleiteado (R$)</th>
                        <th>Fonte Pagadora</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <span class="table-text">5688664-48.2024</span>
                        </td>
                        <td>
                            <span class="table-text">Pembrolizumabe</span>
                        </td>
                        <td>
                            <span class="table-text">40.783,92</span>
                            <div class="table-bar" style="width: 3%;"></div>
                        </td>
                        <td>
                            <span class="table-text">Ipasgo (GO)</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="table-text">5122485-92.2024</span>
                        </td>
                        <td>
                            <span class="table-text">Pembrolizumabe</span>
                        </td>
                        <td>
                            <span class="table-text">170.000,00</span>
                            <div class="table-bar" style="width: 11%;"></div>
                        </td>
                        <td>
                            <span class="table-text">Estado de GO (SUS)</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="table-text">202411801605</span>
                        </td>
                        <td>
                            <span class="table-text">Pembrolizumabe</span>
                        </td>
                        <td>
                            <span class="table-text">10.000,00</span>
                            <div class="table-bar" style="width: 1%;"></div>
                        </td>
                        <td>
                            <span class="table-text">Estado de SE/Aracaju</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="table-text">5980068-02.2024</span>
                        </td>
                        <td>
                            <span class="table-text">Pembrolizumabe</span>
                        </td>
                        <td>
                            <span class="table-text">1.539.965,70</span>
                            <div class="table-bar" style="width: 100%;"></div>
                        </td>
                        <td>
                            <span class="table-text">Ipasgo (GO)</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="table-text">5877812-78.2024</span>
                        </td>
                        <td>
                            <span class="table-text">Imunoglobulina Humana</span>
                        </td>
                        <td>
                            <span class="table-text">244.884,60</span>
                            <div class="table-bar" style="width: 16%;"></div>
                        </td>
                        <td>
                            <span class="table-text">Estado de GO (SUS)</span>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <span class="table-text">5275973-25.2024</span>
                        </td>
                        <td>
                            <span class="table-text">Imunoglobulina Humana</span>
                        </td>
                        <td>
                            <span class="table-text">10.000,00</span>
                            <div class="table-bar" style="width: 1%;"></div>
                        </td>
                        <td>
                            <span class="table-text">Central Nacional Unimed</span>
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>
    </section>

    <!-- Recomenda√ß√µes -->
    <section>
        <h2 class="section-title"><i class="fas fa-clipboard-check"></i> Recomenda√ß√µes Estrat√©gicas</h2>
        
        <div class="grid-2">
            <div>
                <div class="chart-title">Para Advogados</div>
                <div class="process-highlight">
                    <ol style="padding-left: 20px; margin-bottom: 0;">
                        <li style="margin-bottom: 15px;"><strong>Fundamenta√ß√£o T√©cnica:</strong> Enfatizar prescri√ß√£o m√©dica espec√≠fica e relat√≥rios detalhados que demonstrem a inefic√°cia das alternativas convencionais, dando especial aten√ß√£o a casos oncol√≥gicos em est√°gio avan√ßado.</li>
                        <li style="margin-bottom: 15px;"><strong>Estrat√©gia Processual:</strong> Solicitar parecer do NATJUS previamente √† a√ß√£o e incluir literatura cient√≠fica atualizada como evid√™ncia de efic√°cia dos medicamentos pleiteados (estudos internacionais).</li>
                        <li style="margin-bottom: 0;"><strong>Fundamenta√ß√£o Jur√≠dica:</strong> Basear pedidos na Lei 14.454/2022 (car√°ter exemplificativo do rol da ANS) e no direito constitucional √† sa√∫de (Art. 196), destacando a urg√™ncia do tratamento.</li>
                    </ol>
                </div>
            </div>
            
            <div>
                <div class="chart-title">Para Distribuidoras Farmac√™uticas</div>
                <div class="process-highlight">
                    <ol style="padding-left: 20px; margin-bottom: 0;">
                        <li style="margin-bottom: 15px;"><strong>Gest√£o de Estoque:</strong> Manter disponibilidade cont√≠nua de Pembrolizumabe (Keytruda) e Imunoglobulina Humana para atendimento r√°pido em casos de a√ß√µes judiciais deferidas.</li>
                        <li style="margin-bottom: 15px;"><strong>Canais de Comunica√ß√£o:</strong> Estabelecer canais diretos com fontes pagadoras frequentes (Ipasgo, SUS estadual) para agilizar a log√≠stica de entrega p√≥s-decis√£o judicial.</li>
                        <li style="margin-bottom: 0;"><strong>Planejamento Financeiro:</strong> Preparar estrutura para viabilizar tratamentos de longa dura√ß√£o (2+ anos), principalmente para imunoter√°picos, com protocolos de atendimento urgente.</li>
                    </ol>
                </div>
            </div>
        </div>
        
        <div class="spacer"></div>
        
        <div class="chart-title">Para Gestores de Sa√∫de e Magistrados</div>
        <div class="process-highlight">
            <ol style="padding-left: 20px; margin-bottom: 0;">
                <li style="margin-bottom: 15px;"><strong>Avalia√ß√£o T√©cnica Pr√©via:</strong> Implementar um fluxo de an√°lise r√°pida pelo NATJUS especificamente para medicamentos oncol√≥gicos e imunobiol√≥gicos, que diminua o tempo de resposta para tutelas de urg√™ncia.</li>
                <li style="margin-bottom: 15px;"><strong>Protocolos Padronizados:</strong> Desenvolver protocolos espec√≠ficos para aquisi√ß√£o de Pembrolizumabe (Keytruda) pelo sistema p√∫blico, considerando sua alta frequ√™ncia nas a√ß√µes judiciais e a tend√™ncia de deferimento das tutelas.</li>
                <li style="margin-bottom: 0;"><strong>Gest√£o de Recursos:</strong> Estabelecer parcerias com fornecedores para obten√ß√£o de pre√ßos diferenciados em compras emergenciais por decis√£o judicial, especialmente para tratamentos de longa dura√ß√£o.</li>
            </ol>
        </div>
    </section>

    <!-- Tend√™ncias -->
    <section>
        <h2 class="section-title"><i class="fas fa-chart-line"></i> Tend√™ncias e Perspectivas</h2>
        
        <div class="grid-3">
            <div class="recommendation-card">
                <h3 class="recommendation-title">Padr√µes Jur√≠dicos</h3>
                <ul class="recommendation-list">
                    <li class="recommendation-item">100% das tutelas sendo deferidas para medicamentos oncol√≥gicos</li>
                    <li class="recommendation-item">Fundamenta√ß√£o nas evid√™ncias cient√≠ficas e NATJUS</li>
                    <li class="recommendation-item">Prefer√™ncia por Mandado de Seguran√ßa em casos contra entes p√∫blicos</li>
                </ul>
            </div>
            
            <div class="recommendation-card">
                <h3 class="recommendation-title">Padr√µes M√©dicos</h3>
                <ul class="recommendation-list">
                    <li class="recommendation-item">Predom√≠nio de terapias-alvo e imunoter√°picos</li>
                    <li class="recommendation-item">Dosagens padronizadas (200mg/3 semanas para Keytruda)</li>
                    <li class="recommendation-item">Tratamentos de longa dura√ß√£o (at√© 2 anos)</li>
                </ul>
            </div>
            
            <div class="recommendation-card">
                <h3 class="recommendation-title">Padr√µes Financeiros</h3>
                <ul class="recommendation-list">
                    <li class="recommendation-item">Grande varia√ß√£o de valores (R$ 10 mil a R$ 1,5 milh√£o)</li>
                    <li class="recommendation-item">Ipasgo como principal fonte pagadora</li>
                    <li class="recommendation-item">Alta concentra√ß√£o de processos no TJGO</li>
                </ul>
            </div>
        </div>
    </section>

    <!-- Metadados -->
    <section>
        <div class="metadata">
            <div class="metadata-title">Nota T√©cnica Metodol√≥gica:</div>
            <div class="metadata-item">‚Ä¢ Base de Dados: 6 processos judiciais (TJGO, TJSE) com foco em Pembrolizumabe e Imunoglobulina Humana (2024-2025)</div>
            <div class="metadata-item">‚Ä¢ An√°lise Processual: Classifica√ß√£o de a√ß√µes, tutelas de urg√™ncia, fundamenta√ß√£o jur√≠dica e decis√µes judiciais</div>
            <div class="metadata-item">‚Ä¢ An√°lise M√©dica: Indica√ß√µes terap√™uticas, dosagens, esquemas de tratamento e alternativas dispon√≠veis</div>
            <div class="metadata-item">‚Ä¢ An√°lise Financeira: Valores pleiteados, fontes pagadoras e impacto or√ßament√°rio dos tratamentos</div>
            <div class="metadata-item">‚Ä¢ Relat√≥rio gerado em: 24/04/2025 | MEEDI/integralmed</div>
        </div>
    </section>

    <button class="print-button" onclick="window.print()">
        <i class="fas fa-print"></i>
    </button>
</main>

<footer>
    <div class="container">
        <p>¬© 2025 MEEDI/integralmed - Todos os direitos reservados</p>
        <div class="footer-links">
            <a href="#">Pol√≠tica de Privacidade</a>
            <a href="#">Termos de Uso</a>
            <a href="#">Contato</a>
        </div>
    </div>
</footer>